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ABSTRACT
Metals are commonly found in the environment, household, and workplaces in various forms, and a significant segment of
the population is routinely exposed to the trace amount of metals from variety of sources. Exposure to metals, such as
aluminum, lead, iron, and copper, from environment has long been debated as a potential environmental risk factor for
Alzheimer’s disease (AD) for decades, yet results from in vitro, in vivo, and human population remain controversial. In the
case of copper, the neurotoxic mechanism of action was classically viewed as its strong affinity to amyloid-beta (Ab) to help
its aggregation and increase oxidative stress via Fenton reaction. Thus, it has been thought that accumulation of copper
mediates neurotoxicity, and removing it from the brain prevents or reverse Ab plaque burden. Recent evidence, however,
suggests dyshomeostasis of copper and its valency in the body, instead of the accumulation and interaction with Ab, are
major determinants of its beneficial effects as an essential metal or its neurotoxic counterpart. This notion is also
supported by the fact that genetic loss-of-function mutations on copper transporters lead to severe neurological symptoms.
Along with its altered distribution, recent studies have also proposed novel mechanisms of copper neurotoxicity mediated
by nonneuronal cell lineages in the brain, such as capillary endothelial cells, leading to development of AD neuropathology.
This review covers recent findings of multifactorial toxic mechanisms of copper and discusses the risk of environmental
exposure as a potential factor in accounting for the variability of AD incidence.
Key words: inflammation; immunotoxicology; neurotoxicity; metals; neurotoxicology, environmental toxicology.
ALZHEIMER’S DISEASE AND RISK FACTORS
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder associated with behavioral and psychological symp-
toms of dementia (BPSD) among elderly. It is characterized by
pathological buildup of amyloid-beta (Ab) plaques, neurofibril-
lary tangles (NFTs), and neuroinflammation, together with ex-
tensive synaptic and neuronal loss. The gradual but irreversible
progression of such neuroanatomical changes in AD takes place
over a few decades, yet clinical symptoms, like cognitive decline
and BPSD, are not evident until neuropathological features are
advanced. To date, aging is known as an essential concomitant
of AD, and genetic predisposition also plays a significant role
in the onset of this disorder (Bettens et al., 2013). Recent
genome-wide association studies and linkage analyses have
identified multiple susceptible genes that moderately to sub-
stantially increase the risk for late-onset AD (Mukherjee et al.,
2017). Heritability for AD is supported by a large-scale twin
study indicating that approximately 60% of AD cases have a her-
itable component (Gatz et al., 1997). However, only 20% of these
cases are fully explained by currently known susceptible genes
or mutations (Sullivan et al., 2012). Therefore, nonheritable,
nongenetic factors are predicted to contribute considerably to
triggering neurodegeneration and cognitive decline by interact-
ing with susceptible genes and aging (Sato and Morishita, 2013).
In an effort of searching such factors, a number of epidemiologi-
cal studies and meta-analyses have highlighted potentially
modifiable risk factors related to lifestyle, medical history, and
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exposure to occupational and environmental pollutants, such
as pesticides, polluted air, and heavy metals (Yegambaram
et al., 2015). However, the identification of specific environmental
risk factors for AD is extremely challenging because of the long la-
tency of the prodromal and cognitively normal phase prior to the
clinical manifestations of AD, and because exposure to environ-
mental contaminants could be variable throughout life.
HISTORICAL OVERVIEW OF EXPOSURE TO
METALS AND AD—LESSONS FROM
ALUMINUM NEUROTOXICITY
Determining a causative relationship between environmental
risk factors and the onset of AD has been the subject of
criticisms and controversial discussions. Unlike genetic risk fac-
tors that are incorporated in individuals throughout their life,
environmental risk factors vary depending on their lifestyle,
residence, and occupation, making it difficult to tie any particu-
lar exposure with the increased onset of AD. In addition, some
criticisms argue the lack of convincing evidence on the presence
of contaminants in AD brains, epidemiological or population-
based studies to associate the exposure with the incident of AD,
and neurotoxic mechanisms of contaminants in laboratory
models at environmentally relevant dosages. Although fully
addressing these criticisms was challenging in earlier works,
today’s advancement of analytical techniques, methodology,
and high-throughput analyses allows us to revisit previously
questioned modifiable risk factors once again to discover new
cellular and molecular mechanisms of action leading to AD and
accelerated cognitive decline. Aluminum (Al) is historically
argued on the topic of environmental impact in AD.
Epidemiological studies were unable to determine causative
link between Al and AD, though a meta-analysis of 9 indepen-
dent studies where urinary Al concentrations were measured,
reported that cognitive performance was impaired with escalat-
ing Al concentrations (Meyer-Baron et al., 2007). Advancement
of analytical methods using freshly prepared and/or unfixed
brain tissues by laser microprobe mass analysis (Bouras et al.,
1997), neutron activation (Andrasi et al., 2005), energy-dispersive
X-ray spectroscopy with transmission electron microscopy
(Yumoto et al., 2009), and luminogallion fluorescent microscopy
(Mirza et al., 2017) have later reconfirmed the presence of Al in
plaques and NFTs in AD brains. There is, however, the possibility
that high Al in AD brains may be an epiphenomenon, not causa-
tive but consequent to disruption of the blood brain barrier (BBB)
despite the evidence that Al crosses the BBB and disturbs cellular
mechanisms to lead impaired cognition in experimental animal
models. More comprehensive findings and combined efforts of
clinical, epidemiological, and laboratory-based studies will be re-
quired to show the causative role of Al, a nonessential metal.
Thus, it is not hard to imagine that unveiling a causative link, if
any, between copper and AD is even more challenging as it is an
essential metal and has critical physiological functions for cellu-
lar survival. The major question is how and when the essential
metal ever exhibits neurotoxicity.
BENEFICIAL AND DETRIMENTAL ROLE OF
COPPER LINKING TO AD
Sources of Environmental Cu Exposure and Its Valency
Copper (Cu) is an essential transition metal serving as a cata-
lytic cofactor for more than 20 enzymes, particularly those
involved in cellular respiration and energy metabolism,
neurotransmitter biosynthesis, iron metabolism, gene tran-
scription, and antioxidant defense (Itoh et al., 2009). The major
source of daily Cu intake is dietary, with approximately 75%
from solid food and 25% from drinking water (Brewer, 2015).
The preponderance of Cu found in solid food is present in or-
ganic molecules as the cuprous Cuþ form (Ceko et al., 2014),
while that found in drinking water is in the inorganic cupric
Cu2þ form. This difference in the valency of Cu could result in
differential mechanisms of absorption and distribution in the
body. The average Cu intake from drinking water is 0.1 to 1 mg/
d. To a lesser extent, exposure to polluted air is another source
of inorganic Cu. It is released to the atmosphere through an-
thropogenic processes, such as combustion of fossil fuels and
agricultural chemicals, and is associated with particulate mat-
ter (PM), dusts, and mists (Fang et al., 2011; Fernandez et al.,
2002). Cu in PM is found to be elemental form, a form of oxide,
sulfate or carbonate, mostly as its inorganic form of Cu2þ
(Fernandez et al., 2002). Its concentration in atmosphere ranges
from a few nanograms per m3 to 200 ng/m3 in the United States,
and the concentration may reach up to 5000 ng/m3 near smel-
ters and mines. When an average individual inhales 11 000 L of
air per day, 55 lg of Cu would be inhaled together, potentially
associated with long-term environmental and occupational ex-
posure to cause adverse health effects. The impact of Cu expo-
sure through inhalation might elicit greater toxicity in the
central nervous system (CNS) than that through gastrointestinal
tracts because Cu may acquire the ability to bypass the BBB de-
fense via olfactory nerves when it is associated with fine or
ultrafine PM (Block and Calderon-Garciduenas, 2009), as has
been shown for manganese on fine PM (Elder et al., 2006;
Guarneros et al., 2013).
Cu Absorption, Distribution, and Homeostasis
Brain contains as much Cu as liver does, and its proper distribu-
tion, transport, and removal are crucial in order to fulfill its bio-
chemical and physiological functions reactions (Lech and
Sadlik, 2007). Brain also have additional network of proteins
that bind to Cu and control Cu homeostasis including amyloid
precursor protein (APP) and prion protein. These proteins are
considered as primary culprits for major neurodegenerative dis-
eases, AD, and Prion disease, respectively.
In the body, Cu is absorbed from the surface of the intestinal
microvilli as cuprous (Cuþ) by the Cu transporter 1 (CTR1)
(Prohaska, 2008), while less is known about the absorption of cu-
pric (Cu2þ), which is possibly absorbed through divalent metal
transporter 1 or other shared metal transporters. Evolutionally,
it appears that essential Cu is primarily supplied from food
sources as Cuþ. Cu2þ, on the other hand, may have limited nu-
tritional value and exhibit dichotomous health effects in the
body. A fraction of Cu2þ may bypass the normal uptake process
and directly enter the blood stream and increase free Cu levels
as described below (Medeiros, 2011).
Once in the cell, various Cu chaperones distribute it to
organelles and enzymes or excrete it from the cell via special-
ized Cu transporters, ATP7A and ATP7B. ATP7A is primarily
expressed in the basal plasma membrane of intestinal cells to
mediate Cuþ efflux. ATP7B is highly expressed in the liver and
moderately in the brain, and is localized in the transGolgi net-
work of these cells to mediate cellular Cu distribution and ex-
cretion. Genetic loss-of-function mutations of ATP7A result in
systemic Cu deficiency due to inability of intestinal cells to
transport and distribute absorbed Cuþ to the rest of the body,
and are well-known cause of Menkes disease, while genetic
loss-of-function mutations of ATP7B result in excessive
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accumulation of Cu particularly in the liver and brain due to its
inability to excrete Cu, causing Wilson disease. Both inherited
diseases commonly exhibit neurological and neuropsychiatric
impairments including cognitive decline, suggesting that both
Cu deficiency and excess, in other words, Cu dyshomeostasis in
either direction, could trigger severe neurological damage in the
brain. Recent genetic evidence to further support the link be-
tween Cu dyshomeostasis and AD is the identification of poly-
morphisms in the ATP7B gene as an increasing risk for AD
(Bucossi et al., 2012; Liu et al., 2013), and polymorphic ATP7B is
suspected to functional alterations and perturbation of Cu ho-
meostasis (Squitti et al., 2013). Expression of AD-susceptible
ATP7B (K832R) polymorphism is determined as the loss-of-
function variant in a Drosophila model (Mercer et al., 2017), and
the presence of ATP7B (K832R) increases the accumulation of Cu
in multiple organs including liver and brain, and may exert mul-
tiple toxic mechanisms leading to buildup of Ab species
(Figure 1) .
Is Cu a Potential Biomarker to Predict AD?
Most of the Cu in the body is bound to Cu-binding chaperones
and enzymes, such as ceruloplasmin (Cp), superoxide dismut-
ase (SOD), catalase, and Cu chaperone for SOD (CCS). In the
brain, additional Cu binding proteins, such as APP and prion
protein, will bind to Cu and control its homeostasis as described
earlier. The amount of dietary Cu intake, however, does not ap-
pear to reflect the levels of Cu measured in the serum, CSF, or
brain tissues. In AD, CSF Cu levels are inconsistent ranging from
elevated to no change or even decreased when compared with
nondemented individuals. It is, however, worth noting that a
study analyzing 260 subjects found that Cu in CSF is the only
metal showing high variability among AD patients (9–109 lg/l,
median 18 lg/l) compared with control (13–35 lg/l, median 18
lg/l) (Gerhardsson et al., 2008), suggesting that there is a greater
dysregulation of Cu homeostasis in AD brain. Cu levels in the
brain tissues from AD is significantly reduced by 13.8% com-
pared with nondemented group by a meta-analysis of 7 avail-
able reports (Schrag et al., 2011), and this finding is further
supported by recent studies as described later in this review
(Akatsu et al., 2012; Xu et al., 2017). On the other hand, the levels
of Cu in serum, particularly existing as nonCp-bound Cu, are
found to be significantly increased and positively correlated
with the severity of cognitive decline, reduced CSF Ab, and in-
creased CSF tau in mild cognitive impairment (MCI) and AD
patients (Squitti et al., 2006, 2011; Talwar et al., 2017; Vural et al.,
2010). The exact sources of nonCp-bound Cu in serum remain
unknown, though impairment of proper Cu transport and distri-
bution by chaperone proteins or increased exposure to Cu2þ and
subsequent leakage to the blood stream may be potential fac-
tors to elevate these “free” Cu in serum. Individuals with high
serum nonCp-bound Cu also convert from MCI to AD by 2.5
years faster than those with low serum nonCp-bound Cu
(Squitti et al., 2014), indicating that free Cu in serum could serve
as a potential biomarker to predict the progression from MCI to
AD. This inverse relationship between Cu and one’s cognitive
performance has been reported not only among MCI/AD
patients but also among cognitively normal individuals (Salustri
et al., 2010). However, the environmental origins of Cu exposure
or differential metabolic processes causing excess elevated free
Cu in serum in these cohorts remain undetermined.
Discordance of Cu levels in CSF, brain tissues, and serum in AD
patients points to a systemic imbalance of Cu homeostasis and
impaired distribution of Cu causing deficiency in the CSF and
excess free Cu in the circulation. In this regard, therapeutic
Figure 1. Schematic diagram illustrating the proposed mechanisms of Cu’s effects in the brain. BBB is important to modulate Cu transport and Ab clearance. Cu(I)
presents M2 phenotype and prevents inflammation while converted to Cu(II) promotes the down-regulation of LRP1 in capillary endothelial cells, formation of
Cu(II)-Ab complex, ROS generation, and impairment of microglial phagocytosis. In addition, increased proinflammatory cytokine production also down-regulates LRP1,
further exacerbating Ab depositions in brain parenchyma. Astrocytes uptake excess Cu via CTR1 and sequestering it with glutathione (GSH) and metallothionein (MT)
to protect cells against reactive oxygen and nitrogen species (ROS/RNS). K832R polymorphism on ATP7B is recently identified as loss-of-function polymorphism,
enhances the accumulation of Cu in various organs including brain, and increases the risk for developing AD.
340 | TOXICOLOGICAL SCIENCES, 2018, Vol. 163, No. 2
D
ow
nloaded from
 https://academ
ic.oup.com
/toxsci/article-abstract/163/2/338/4835389 by guest on 09 June 2020
interventions to restore brain Cu levels may promote neuropro-
tection through upregulating brain’s bioenergetics and anti-
oxidative defense (Quinn et al., 2009). However, Cu
supplementation may not be a suitable approach to restore
brain Cu, and 12-month clinical trial of 8 mg Cu did not rescue
nor worsen cognitive outcomes in mild AD patients (Kessler
et al., 2008).
On the other hand, among cognitively normal elderly, unin-
tentional overdosing of Cu intake, mainly from over-the-
counter nutritional and dietary supplements, together with
high dietary fat exhibited almost 5 times accelerated cognitive
decline relative to those who had high dietary fat but low daily
Cu intake (Morris et al., 2006). Detrimental effect of Cu is potenti-
ated by other dietary factors with unknown mechanisms. High
Cu intake by itself did not improve cognitive score, in agree-
ment with finding from the Cu supplementation clinical trial in
AD described earlier. Taken together, these findings cannot rule
out the possibility that excess intake of inorganic Cu increases
the risk of incurring cognitive decline.
Studies to Determine the Link Between Cu and AD
Toxic mechanisms of action of Cu—promoting Ab buildup and
oxidative damage. The physical interaction and binding affinity
of Cu to extracellular domain of APP and Ab species have been
extensively studied and shown to promote Ab production and
fibrillization in vitro (Atwood et al., 2000; Huang et al., 1999).
Within the Ab sequence, the redox-active Cu2þ, but not Cuþ, is
coordinated to the histidine (His6, His13, and His14) or Tyr10
residues. This coordination leads to formation of the Cu(II)-Ab
complex (predominantly with 1:1 stoichiometry) and aggrega-
tion process that involves a conformational change (Tougu
et al., 2011; Yugay et al., 2016). Classically, the Cu(II)-Ab complex
is thought to generate reactive oxygen species (ROS) and medi-
ate oxidative damage through Fenton-type reaction and impair-
ment of mitochondrial function (Jiang et al., 2007). This
hypothesis further reinforces Cu2þ from environmental sources
could elicit rather detrimental effects while Cuþ from dietary
sources fulfills biologically essential demand.
One of early milestone in vivo studies investigating Cu expo-
sure in AD was conducted by Sparks and colleagues who
reported that chronic exposure to a trace amount of Cu (0.12
ppm), but not zinc or Al, in drinking water, together with high
cholesterol (2%) diet for 8 weeks promoted Ab plaque formation
and learning deficits in rodent models (Sparks et al., 2006;
Sparks and Schreurs, 2003). Upregulation of ATP-binding cas-
sette transporter A1 (ABCA1) was strongly induced in several
brain regions of cholesterol-fed animals with Cu in drinking wa-
ter but not to the extent with Al or zinc in drinking water
(Schreurs and Sparks, 2016). ABCA1 upregulation generally pro-
motes cellular cholesterol efflux through ApoE lipidation and
lowers cellular Ab generation (Kim et al., 2015). High cholesterol
diet with Cu in drinking water, however, may outweigh ABCA1-
mediated Ab clearance in the brain of those animals. A recent
study reveals that cholesterol-enriched diet significantly
increases the levels of N-truncated Ab species (Perez-
Garmendia et al., 2014), which are now commonly detected in
the brains from AD and Down syndrome patients within the
cores of Ab plaques (Wirths et al., 2017). N-truncated Ab species
have stronger affinity for Cu2þ than naı¨ve forms and promote
aggregation of Ab in vitro (Mital et al., 2015), suggesting that the
combined effect of Cu and cholesterol leads to accelerated ag-
gregation propensity of Ab and forms the seeding cores for pla-
ques. Quantification of various N-truncated Ab species in Cu/
cholesterol-fed animals would provide additional key evidence
to validate whether this mechanism plays a dominant role in
the accelerated buildup of Ab plaques.
On the contrary, in vivo evidence also supports Cu supple-
mentation as protective strategy to reduce Ab plaques in trans-
genic mouse model of AD. APP is additional Cu-binding protein
in the brain, and mice overexpressing APP transgene develop a
reduced brain Cu possibly because excess APP binds to Cu and
excrete it from the brain (Bayer et al., 2003; Maynard et al., 2002;
Needham et al., 2014). The interaction between APP expression
and cellular Cu levels is also demonstrated in cell culture mod-
els (Armendariz et al., 2004; Bellingham et al., 2004a,b). Thus, res-
toration of brain Cu levels in the APP transgenic mouse model
by Cu supplementation resulted in the reduction of Ab produc-
tion and increased antioxidant capability by stabilizing SOD ac-
tivity possibly through increased CCS-mediated cellular Cu
transport (Bayer et al., 2003). Whether this beneficial effect of Cu
observed in mice can be applied directly to humans and AD
remains ongoing discussion. To date, although there is no evi-
dence supporting a strong correlation between APP expression
and brain Cu levels in AD, Down syndrome, or individuals with
APP duplication gene, recent studies carefully quantified Cu in
brain tissues by inductively coupled-plasma mass spectrometry
and determined a significant reduction of Cu in several brain
regions including hippocampus, amygdala, entorhinal cortex,
and cerebellum among AD patients (Akatsu et al., 2012; Xu et al.,
2017). The reduced levels of cellular Cu in AD brain tissues are
comparable of those observed in Menkes disease.
Unfortunately, changes in APP levels in these cohorts were not
available, so it cannot be determined whether reduction of Cu is
mediated by upregulation of APP and buildup of Ab in the brain,
or merely a consequence of extensive neurodegeneration in
these regions. In 3xTg-AD mouse model, however, the high
dose Cu in drinking water induced detrimental effects include
accelerated cognitive impairment and increased Ab and tau
buildup by upregulating the activities of a- and b-secretase and
by activating cdk5/p25 (Kitazawa et al., 2009; Yu et al., 2015b). In
addition to nonphysiological dose of Cu supplementation, addi-
tional PS1 and tau transgenes in 3xTg-AD mice, background
strain, duration of the study, and other differences may contrib-
ute to the discrepancy of results, but these findings represent
complexity of beneficial and toxic effects and mechanisms of
Cu, in part may be attributed by its valency, in the biological
system.
Metal chelation as a possible therapeutic approach for AD. Initial
findings from clinical studies supported that excess Cu in the
body contributed to the accelerated Ab aggregation and buildup,
leading to the onset of AD. Thus, removing excess Cu could be a
potential therapeutic intervention to ameliorate AD neuropa-
thology. Preclinical testing of metal chelators, clioquinol and
DP-109, demonstrated a significant reduction of cerebral Ab de-
posit in Tg2576 mice (Cherny et al., 2001; Lee et al., 2004). Shortly
after, derivative of clioquinol, PBT2 was introduced in
preclinical studies and phase II clinical trials. Despite a remark-
able reduction of Ab and restoration of synapses in animal mod-
els, outcomes from clinical trials in prodromal or early stages of
AD patients were not promising (Lannfelt et al., 2008). Potential
concerns of the use of metal chelators point out that Cu deple-
tion by the chelator may reduce Cu-Ab interaction and fibrilliza-
tion, but leading to the buildup of soluble, smaller, and
presumably more neurotoxic Ab species like Ab dimers in the
brain (Goch and Bal, 2017). This is consistent with the idea that
Ab plaques are in fact biologically inert and shielded by micro-
glia processes to contain its neurotoxicity (Yuan et al., 2016).
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Novel toxic mechanisms of Cu leading to AD—beyond its interaction
with Ab. In the light of recent findings, Cu may exhibit multiple
toxic mechanisms in nonneuronal cell lineages in the brain and
promote Ab buildup without directly interacting with it. Chronic
exposure to 0.13 ppm Cu in drinking water in APP23 transgenic
mouse model revealed elevated levels of nonCp-bound Cu in
plasma and subsequent downregulation of low-density lipopro-
tein receptor-related protein 1 (LRP1) in capillary endothelial
cells (Singh et al., 2013). A parallel loss of LRP1 is observed in ad-
vanced aging and in AD brains (Kang et al., 2000; Silverberg et al.,
2010), and its genetic ablation in endothelial cells has been
shown to cause parenchymal Ab buildup in mice (Storck et al.,
2016). Since this mechanism does not require Cu to cross the
BBB and enter the CNS, rather peripheral “free” Cu triggering
the loss of LRP1 in endothelial cells, it is well in line with the
clinical observations that elevated Cu levels in plasma, but not
in CSF or brain, correlate well with the progression and cogni-
tive decline in AD as described earlier. On the other hand, as
chronic Cu exposure down-regulates LRP1 in capillary endothe-
lial cell and promotes Ab buildup, excessive Ab could further
impair its own efflux from brain to blood by oxidizing LRP1,
leading to increased Ab deposition in the brain (Jeynes and
Provias, 2008). Thus, Cu toxicity could significantly impair
brain’s Ab clearance mechanism and promote Ab buildup.
In addition to its impact on endothelial cells, Cu plays an im-
portant role in maintaining the immune homeostasis (Zucconi
et al., 2007), and deficiency or excess Cu differentially alters
microglial phenotypes. The involvement of microglia and neu-
roinflammation in AD has recently emerged as a significant fac-
tor and unregulated activation of microglia and astrocytes
promotes excessive synaptic pruning, impairment of Ab clear-
ance, and neurotoxicity (Hong et al., 2016; Liddelow et al., 2017;
Yuan et al., 2016). A study using murine monocyte BV2 cells
reported that Cuþ can polarize cells from a proinflammatory M1
phenotype to a protective antiinflammatory M2 phenotype via
inhibition of nitric oxide production (Rossi-George et al., 2012).
This finding supports the concept that the cuprous Cuþ form
acts in a physiologically protective. On the other hand, BV2 cells
exposed to Cu2þ had impaired phagocytosis and increased re-
lease of proinflammatory cytokine, such as IL-1b, IL-6, and
TNFa, following Ab stimulation (Kitazawa et al., 2016), suggest-
ing the cupric Cu2þ form perturbs innate inflammatory
responses. The Cu(II)-Ab complex also enhanced microglia-
mediated neuronal damage by causing increased production of
ROS and nitric oxide, while Cu(II) or Ab alone did not cause
these adverse effects (Yu et al., 2015a). In the TgCRND8 AD mice
model, activated microglia might play a modulatory role via up-
take of extracellular Cu and upregulation of ATP7A expression
to sequester intracellular Cu from Golgi to cytoplasmic vesicles.
Therefore, limiting free extracellular Cu, available for complex-
ing with Ab and subsequent phagocytosis of the Cu(II)-Ab com-
plex, may prevent plaque formation and inflammation (Zheng
et al., 2010). Collectively, the valency of Cu is a critical determi-
nant in the regulation of microglial phenotype and differential
toxicity in the brain.
Astrocytes can actively restore and resist against Cu-
induced toxicity in part because astrocytes have a high capacity
to uptake excess Cu via CTR1 and sequestering it in glutathione
and metallothionein complex, key endogenous antioxidant
molecules to protect cells against ROS (Bulcke and Dringen,
2015; Scheiber and Dringen, 2011). Astrocyte dysfunction by ag-
ing or other means, together with environmental Cu exposure
may result in the loss of neuroprotective and antioxidative
capacity of the brain and increased susceptibility to cognitive
decline and AD.
Overall, results from these studies suggest that not only the
direct interaction of Cu with APP or Ab and neurons, but also
the effect of Cu on nonneuronal cell lineages significantly con-
tributes to the development and progression of AD neuropa-
thology (Figure 1). Further research should be directed to
provide new insights into potential interactive mechanisms be-
tween endothelium, microglia, astrocyte and neuron of Cu
exposure.
FUTURE DIRECTIONS
Studies from in vitro and in vivo models have indicated new
ways by which Cu potentiates the hallmark neuropathology of
AD. This is in addition to their known ability to interact with Ab
and promote oxidative damage, both of which are generally
considered as major neurotoxic mechanisms of action. Cu-
induced loss of endothelial LRP1, dysregulation of inflamma-
tion, and epigenetic modifications are currently being studied,
and their key involvements in AD are soon to be uncovered.
Since both neuroinflammation and epigenetic modifications are
readily initiated by environmental insults, the current direction
of the research further substantiates the capacity of environ-
mental risk factors to facilitate AD.
It is extremely challenging to determine the level of contri-
bution from a single environmental risk factor in humans as
dose, duration, route, and timing of the exposure vary from in-
dividual to individual, and multiple exposures and conditions
are commonly involved throughout one’s lifetime. Especially,
since Cu is an essential metal, its beneficial effects should al-
ways be considered from its biological functions. Sources of Cu
exposure and its valency found in the body or brain, but not the
absolute amount, may be more relevant with accelerated cogni-
tive decline or the onset of AD. The use of transgenic animal
models is still one of valuable research tools to decipher the
routes by which Cu and other metals can exert their neurotoxic
effects, leading to AD neuropathology. Yet, the selection of ap-
propriate model should be carefully considered especially for
Cu study as APP overexpression may significantly lower brain’s
Cu homeostasis and would not be physiologically relevant to
AD. A recent APP knock-in mouse model circumvents this po-
tential issue. In addition, application of unbiased omics techni-
ques will provide supporting evidence and may help identify
novel pathways associated with metal toxicity leading to
neurodegeneration.
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